These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25685284)

  • 21. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
    Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
    Takasu T; Takakura S
    Life Sci; 2019 Aug; 230():19-27. PubMed ID: 31125563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
    Tahara A; Takasu T
    Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
    Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Kayama Y; Takeda N; Minamisawa S; Utsunomiya K
    Sci Rep; 2017 Sep; 7(1):11906. PubMed ID: 28928461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
    Tahara A; Takasu T
    Life Sci; 2018 Mar; 197():80-90. PubMed ID: 29425766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
    Song P; Onishi A; Koepsell H; Vallon V
    Expert Opin Ther Targets; 2016 Sep; 20(9):1109-25. PubMed ID: 26998950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring.
    Kawaguchi Y; Sawa J; Kumeda Y
    Diabetes Ther; 2020 Dec; 11(12):2945-2958. PubMed ID: 33063270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
    Takakura S; Toyoshi T; Hayashizaki Y; Takasu T
    Life Sci; 2016 Feb; 147():125-31. PubMed ID: 26829386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.
    Ueno H; Nakazato H; Ebihara E; Noma K; Kawano T; Nagamine K; Sakoda H; Nakazato M
    Diabetes Ther; 2018 Feb; 9(1):403-411. PubMed ID: 29322485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT).
    Tanaka A; Imai T; Toyoda S; Sugimoto K; Yoshida R; Furuta M; Node K;
    Diabetol Metab Syndr; 2023 Jul; 15(1):152. PubMed ID: 37415229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of SGLT2 Inhibitor Ipragliflozin on Cardiac Hypertrophy and microRNA Expression Profiles in a Non-diabetic Rat Model of Cardiomyopathy.
    Takasu T
    Biol Pharm Bull; 2022; 45(9):1321-1331. PubMed ID: 36047201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials.
    Kashiwagi A; Shestakova MV; Ito Y; Noguchi M; Wilpshaar W; Yoshida S; Wilding JPH
    Diabetes Ther; 2019 Dec; 10(6):2201-2217. PubMed ID: 31606880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First case of drug eruption due to ipragliflozin: Case report and review of the literature.
    Saito-Sasaki N; Sawada Y; Nishio D; Nakamura M
    Australas J Dermatol; 2017 Aug; 58(3):236-238. PubMed ID: 27242192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
    Komatsu S; Nomiyama T; Numata T; Kawanami T; Hamaguchi Y; Iwaya C; Horikawa T; Fujimura-Tanaka Y; Hamanoue N; Motonaga R; Tanabe M; Inoue R; Yanase T; Kawanami D
    Endocr J; 2020 Jan; 67(1):99-106. PubMed ID: 31776304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
    Du F; Hinke SA; Cavanaugh C; Polidori D; Wallace N; Kirchner T; Jennis M; Lang W; Kuo GH; Gaul MD; Lenhard J; Demarest K; Ajami NJ; Liang Y; Hornby PJ
    J Pharmacol Exp Ther; 2018 Jun; 365(3):676-687. PubMed ID: 29674332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.